The UK government two-week rule and its impact on melanoma prognosis: An evidence-based study

Annals of the Royal College of Surgeons of England

Volumn 89, Issue 6, 2007, Pages 609-615

  Pacifico, M D ^a   Pearl, Robert A ^a   Grover, R ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Melanoma; Pigmentd lesion clinic; Two week rule

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CONSULTATION; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; GENERAL PRACTITIONER; GOVERNMENT; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PATIENT REFERRAL; PRACTICE GUIDELINE; PROGNOSIS; RANK SUM TEST; RETROSPECTIVE STUDY; SKIN CANCER; SURVIVAL TIME; TUMOR VOLUME; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; ENGLAND; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; FEMALE; GOVERNMENT PROGRAMS; HEALTH POLICY; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; REFERRAL AND CONSULTATION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; WAITING LISTS;

EID: 34548648599     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588407X205459     Document Type: Article

References (39)

1. Survival of cancer patients in Europe: The EOROCARE-2 study. Lyon: IARC Scientific Publications, 1999; 1-572.
2. Jones R, Rubin G, Hungin P. Is the two week rule for cancer referrals working? BMJ 2001; 323: 24-8.
3. Severi G, Giles GG, Robertson C, Boyle P, Autier P. Mortality from cutaneous melanoma: evidence for contrasting trends between populations. Br J Cancer 2000; 82: 1887-9.
4. MacKie RM, Bray CA, Hole DJ, Morris A, Nicolson M, Evans A et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-91.
5. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
6. Temoshok LR, DiClemente J, Sweet DM, Blois MS, Sagebiel RW. Factors related to patient delay in seeking medical attention for cutaneous malignant melanoma. Cancer 1984; 54: 3048-53.
7. Cancer Guidelines Sub-Group of the COG. Guidance on commissioning cancer services, improving outcomes in colorectal cancer: the research evidence. Leeds: NHS Executive, 1997.
8. Rosjhan Lall C, Leinster S, Mithell S, Holcombe C. Current patterns of referral in breast disease. Breast 2000; 9: 334-7.
9. Grover R, Ross DA, McKelvie M, Morgan BD. Improving the early detection of malignant melanoma. Ann R Coll Surg Engl 1996; 78: 176-9.
10. Pacifico MD, Grover R, Sanders R. Use of an early detection strategy to improve disease control in melanoma patients. Br J Plast Surg 2004; 57: 105-11.
11. Moreea S, Green J, MacFie J, Mitchell CJ. Impact of the two week waiting time standard on the gastroenterology service of a district general hospital. Gut 2001; 48 (Suppl): A3.
12. Soo FY, Winterton R, Plusa SM. Impact of the '2 week rule' on the treatment of colorectal cancer. Gut 2001; 48 (Suppl): A53.
13. Oliver MD. All stages of care pathway need speeding up. BMJ 2001; 323: 864.
14. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999; 353: 1119-26.
15. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.
16. Herd RM, Cooper EJ, Hunter JA, McLaren K, Chetty U, Watson AC et al. Cutaneous malignant melanoma. Publicity, screening clinics and survival - the Edinburgh experience 1982-90. Br J Dermatol 1995; 132: 563-70.
17. Smethurst DP, Williams HC. Are hospital waiting lists self-regulating? Nature 2001; 410: 652-3.
18. MacKenzie-Wood AR, Milton GW, De Launey JW. Melanoma: accuracy of clinical diagnosis. Aust J Dermatol 1998; 39: 31-3.
19. Morton CA, MacKie RM. Clinical accuracy of the diagnosis of cutaneous malignant melanoma. Br J Dermatol 1998; 138: 283-7.
20. Carli P, De Giorgi V, Nardini P, Mannone F, Palli D, Giannotti B. Melanoma detection rate and concordance between self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in Italy. Br J Dermatol 2002; 146: 261-6.
21. Graham-Brown RA, Osborne JE, London SP, Fletcher A, Shaw D, Williams B et al. The initial effects on workload and outcome of a public education campaign on early diagnosis and treatment of malignant melanoma in Leicestershire. Br J Dermatol 1990; 122: 53-9.
22. Bataille V, Sasieni P, Curley RK, Cook MG, Marsden RA. Melanoma yield, number of biopsies and missed melanomas in a British teaching hospital pigmented lesion clinic: a 9-year retrospective study. Br J Dermatol 1999; 140: 243-8.
23. O'Connor WJ, Barnes L. Melanoma - a five year audit. Irish Med J 1999; 87: 138-9.
24. Duff CG, Melsom D, Rigby HS, Kenealy JM, Townsend PL. A 6 year prospective analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts miss malignant melanomas, but not often. Br J Plast Surg 2001; 54: 317-21.
25. Paine SL, Cockburn J, Noy SM, Marks R. Early detection of skin cancer, knowledge, perceptions and practices of general practitioners in Victoria. Med J Aust 1994; 161: 188-9.
26. Ibbotson SH, Dahl MG, Farr PM. Do we need pigmented lesion clinics? Lancet 1995; 346: 1373.
27. MacKie RM, Bray CA, Leman JA. Effect of public education aimed at early diagnosis of malignant melanoma: cohort comparison study. BMJ 2003; 326: 367.
28. MacKie RM, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. BMJ 1992: 304: 1012-5.
29. MacKie RM, Hunter JA, Aitchison TC, Hole D, McLaren K, Rankin R et al. Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group. Lancet 1992; 339: 971-5.
30. de Rooij MJ, Rampen FH, Schouten LJ, Neumann HA. Skin cancer screening focusing on melanoma yields more selective attendance. Arch Dermatol 1995; 131: 422-5.
31. Mihm Jr MC, Clark Jr WH, Reed RJ. The clinical diagnosis of malignant melanoma. Semin Oncol 1975; 2: 105-18.
32. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-82.
33. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer 1998; 34 (Suppl 3): S3-6.
34. Langley RG, Sober AJ: Clinical recognition of melanoma and its precursors. Hematol Oncol Clin North Am 1998; 12: 699-715.
35. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch Pathol Lab Med 2001; 125: 1295-306.
36. McGovern VJ, Mihm Jr MC, Bailly C, Booth JC, Clark Jr WH, Cochran AJ et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973; 32: 1446-57.
37. Mallett RB, Fallowfield ME, Cook MG, Landells WN, Holden CA, Marsden RA. Are pigmented lesion clinics worthwhile? Br J Dermatol 1993; 129: 689-93.
38. Southampton Melanoma Group. Effects of rapid referral on thickness of melanomas. BMJ 1986; 293: 270.
39. Melia J, Moss S, Coleman D, Frost T, Graham-Brown R, Hunter JA et al. The relation between mortality from malignant melanoma and early detection in the Cancer Research Campaign Mole Watcher Study. Br J Cancer 2001; 85: 803-7.